세계의 화학요법 유발성 말초신경병증 치료 시장 기회 및 전략(-2034년)

Chemotherapy induced peripheral neuropathy (CIPN) treatment encompasses a range of therapeutic interventions aimed at alleviating the nerve damage caused by certain chemotherapeutic agents. CIPN manifests as a dose-limiting side effect in approximately 30-40% of patients undergoing chemotherapy, leading to symptoms such as pain, tingling and numbness, primarily in the hands and feet. The treatments are utilized by oncologists, neurologists, pain specialists and primary care physicians to manage these symptoms and improve patient quality of life during and after cancer therapy.

The global chemotherapy induced peripheral neuropathy treatment market was valued at $1,278.08 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 5.00%.

Rising Adoption Of Pain Management Therapies

During the historic period, the rising adoption of pain management therapies supported the growth of the CIPN treatment market. Chemotherapy-Induced Peripheral Neuropathy (CIPN) presents substantial pain and discomfort, prompting increasing interest from both patients and healthcare providers in specialized pain management solutions. The adoption of multimodal treatment strategies-combining pharmacological options such as anticonvulsants and antidepressants with physical therapy and complementary interventions-enhances patient outcomes and supports wider utilization of CIPN-specific therapies. Moreover, successful pain control enables patients to maintain chemotherapy regimens with fewer dose modifications or interruptions, underscoring the critical role of CIPN treatments within comprehensive pain management. For instance, in September 2024, a report by the Health and Global Policy Institute, a Japan-based independent, non-profit health policy think tank, highlighted that the adoption of pain management therapies in Japan is rapidly rising. This trend is primarily driven by the country's aging population and the high prevalence of chronic pain, which affected approximately 22.5% of adults, or around 23.15 million people, in 2023. Therefore, the rising adoption of pain management therapies supported the growth of the CIPN treatment market

Collaborative Research Enhances Understanding Of Chemotherapy-Induced Peripheral Neuropathy

Major companies operating in the CIPN treatment market are adopting collaborative research initiative approach to develop advanced solutions. Strategic partnerships help CIPN treatment companies by combining resources and expertise, enhancing research and development capabilities, expanding market reach and accelerating commercialization, ultimately driving innovation and growth in the CIPN treatment industry. For instance, in July 2025, University of Dundee, a UK-based research university partnered with Eli Lilly and Company, a US-based pharmaceutical company and Versus Arthritis, a UK-based charity focused on supporting individuals with arthritis and musculoskeletal conditions to successfully complete the research phase of the PAINSTORM Dundee Chemotherapy-Induced Peripheral Neuropathy (CIPN) Study. This collaborative effort focused on understanding the causes and progression of CIPN in cancer patients undergoing neurotoxic chemotherapy. The study involved around 200 participants, employing a multifaceted approach that includes quantitative sensory testing, blood biomarker analysis and optional magnetic resonance imaging (MRI) scans. The research aims to identify genetic, clinical and psychosocial risk factors contributing to CIPN, with the ultimate goal of informing personalized prevention and treatment strategies.

The global chemotherapy induced peripheral neuropathy treatment market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 33.13% of the total market in 2023.

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global chemotherapy induced peripheral neuropathy treatment market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for chemotherapy induced peripheral neuropathy treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The chemotherapy induced peripheral neuropathy treatment market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider chemotherapy induced peripheral neuropathy treatment market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by treatment, by drug type, by distribution channel and by end-user.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by drug class, by treatment, by drug type, by distribution channel and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Recent Developments- Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for chemotherapy induced peripheral neuropathy treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Drug Class: Neurotransmitter-Based Therapy; Other Drug Classes
• 2) By Treatment: Medication; Physical Therapy; Other Treatments
• 3) By Drug Type: Branded; Generic
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Research Institutes; Specialty Clinics
• Companies Mentioned: Teva Pharmaceuticals; Aurobindo Pharma Limited; Viatris Inc. (Mylan); Sun Pharmaceutical Industries Ltd.; Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; chemotherapy induced peripheral neuropathy treatment indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Chemotherapy Induced Peripheral Neuropathy Treatment - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Definition And Segmentations
• 6.4 Market Segmentation By Drug Class
  • 6.4.1 Neurotransmitter Based Therapy
  • 6.4.2 Other Drug Classes
• 6.5 Market Segmentation By Treatment
  • 6.5.1 Medication
  • 6.5.2 Physical Therapy
  • 6.5.3 Other Treatments
• 6.6 Market Segmentation By Drug Type
  • 6.6.1 Branded
  • 6.6.2 Generic
• 6.7 Market Segmentation By Distribution Channel
  • 6.7.1 Hospital Pharmacy
  • 6.7.2 Retail Pharmacy
  • 6.7.3 Online Pharmacies
  • 6.7.4 Other Distribution Channels
• 6.8 Market Segmentation By End-User
  • 6.8.1 Hospitals
  • 6.8.2 Research Institutes
  • 6.8.3 Specialty Clinics

7 Major Market Trends

• 7.1 Collaborative Research Enhances Understanding Of Chemotherapy-Induced Peripheral Neuropathy
• 7.2 Advances In Selective FABP5 Inhibitors For Chemotherapy-Induced Peripheral Neuropathy
• 7.3 Strategic Funding Advances Neuroprotective Therapies For Chemotherapy-Related Nerve Damage

8 Global Chemotherapy Induced Peripheral Neuropathy Treatment Growth Analysis And Strategic Analysis Framework

• 8.1 Global: PESTEL Analysis
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis Of End User (B2B) Market
  • 8.2.1 Hospitals
  • 8.2.2 Research Institutes
  • 8.2.3 Specialty Clinics
• 8.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 8.4.1 Market Drivers 2019 - 2024
  • 8.4.2 Market Restraints 2019 - 2024
• 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
• 8.6 Forecast Growth Contributors/Factors
  • 8.6.1 Quantitative Growth Contributors
  • 8.6.2 Drivers
  • 8.6.3 Restraints
• 8.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Total Addressable Market (TAM)

9 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation

• 9.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Neurotransmitter Based Therapy, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Chemotherapy Induced Peripheral Neuropathy Treatment Market, Regional and Country Analysis

• 10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.5 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.6 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market: Country Analysis
• 11.7 China Market
• 11.8 Summary
• 11.9 Market Overview
  • 11.9.1 Country Information
  • 11.9.2 Market Information
  • 11.9.3 Background Information
  • 11.9.4 Government Initiatives
  • 11.9.5 Regulations
  • 11.9.6 Regulatory Bodies
  • 11.9.7 Major Associations
  • 11.9.8 Taxes Levied
  • 11.9.9 Corporate Tax Structure
  • 11.9.10 Major Companies
• 11.10 China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.11 China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.12 China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.13 India Market
• 11.14 India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.15 India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.16 India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.17 Japan Market
• 11.18 Summary
• 11.19 Market Overview
  • 11.19.1 Country Information
  • 11.19.2 Market Information
  • 11.19.3 Background Information
  • 11.19.4 Government Initiatives
  • 11.19.5 Regulations
  • 11.19.6 Regulatory Bodies
  • 11.19.7 Major Associations
  • 11.19.8 Taxes Levied
  • 11.19.9 Corporate Tax Structure
  • 11.19.10 Major Companies
• 11.20 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.21 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.22 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.23 South Korea Market
• 11.24 Summary
• 11.25 Market Overview
  • 11.25.1 Country Information
  • 11.25.2 Market Information
  • 11.25.3 Background Information
  • 11.25.4 Government Initiatives
  • 11.25.5 Regulations
  • 11.25.6 Regulatory Bodies
  • 11.25.7 Major Associations
  • 11.25.8 Taxes Levied
  • 11.25.9 Corporate Tax Structure
  • 11.25.10 Investments
  • 11.25.11 Major Companies
• 11.26 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.27 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.28 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.29 Australia Market
• 11.30 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.31 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.32 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.33 Indonesia Market
• 11.34 Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.35 Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.36 Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate Tax Structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 UK Market
• 12.7 UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.8 UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 Germany Market
• 12.11 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.12 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 France Market
• 12.15 France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.16 France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 Italy Market
• 12.19 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.20 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.21 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Spain Market
• 12.23 Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.24 Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.25 Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Major Companies
• 13.3 Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Russia Market
• 13.7 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.8 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Investments
  • 14.9.11 Major Companies
• 14.10 USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.11 USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.12 USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.17 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.18 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Major Companies
• 15.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.6 Brazil Market
• 15.7 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.8 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Major Companies
• 16.3 Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Major Companies
• 17.3 Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Teva Pharmaceutical Industries Ltd.
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Financial Overview
• 18.3 Aurobindo Pharma Limited
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Financial Overview
• 18.4 Viatris Inc. (Mylan)
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Financial Overview
• 18.5 Sun Pharmaceutical Industries Ltd.
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Financial Overview
• 18.6 Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Lupin Limited
  • 19.1.1 Company Overview
  • 19.1.2 Products And Services
• 19.2 Sandoz Group AG
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
• 19.3 Torrent Pharmaceuticals Ltd
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
• 19.4 Alkem Laboratories Limited
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
• 19.5 Dr Reddys Laboratories Ltd.
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
• 19.6 Apotex Inc.
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
• 19.7 Eli Lilly
  • 19.7.1 Company Overview
  • 19.7.2 Products And Services
• 19.8 WEX Pharmaceuticals
  • 19.8.1 Company Overview
  • 19.8.2 Products And Services
• 19.9 Amgen Inc.
  • 19.9.1 Company Overview
  • 19.9.2 Products And Services
• 19.10 Asahi Kasei Corporation
  • 19.10.1 Company Overview
  • 19.10.2 Products And Services
• 19.11 Eisai Inc.
  • 19.11.1 Company Overview
  • 19.11.2 Products And Services
• 19.12 ESTEVE
  • 19.12.1 Company Overview
  • 19.12.2 Products And Services
• 19.13 ChromaDex Corp.
  • 19.13.1 Company Overview
  • 19.13.2 Products And Services
• 19.14 Apexian Pharmaceuticals Inc.
  • 19.14.1 Company Overview
  • 19.14.2 Products And Services
• 19.15 AnnJi Pharmaceutical Co. Ltd.
  • 19.15.1 Company Overview
  • 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 electroCor Acquired NeuroMetrix

23 Recent Developments In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 23.1 Clinical Data Highlights Potential Of Nadunolimab In Reducing Chemotherapy-Induced Peripheral Neuropathy
• 23.2 New Topical Agent Targeting Sodium Channels Completes Phase II Trial In CIPN

24 Opportunities And Strategies

• 24.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 24.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 24.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies

25 Chemotherapy Induced Peripheral Neuropathy Treatment Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer